Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
Duke Clinical Research Institute
Information provided by (Responsible Party):
Janssen Scientific Affairs, LLC
ClinicalTrials.gov Identifier:
NCT01165710
First received: July 16, 2010
Last updated: September 11, 2014
Last verified: September 2014
  Purpose

The ORBIT-AF registry will be a multicenter, prospective outpatient disease registry to identify "real world" treatment patterns of atrial fibrillation. The registry will describe this patient population with regards to demographics, clinical factors, risk stratification, and geographic regions. In particular, attention will be focused on the utilization, effectiveness, and safety of antithrombotic therapies in the prevention of stroke. The registry is designed to identify reasons and risk factors for non-receipt of anticoagulation (AC) therapy, as well as reasons why AF patients who are prescribed AC therapy do not take them.


Condition Intervention Phase
Atrial Fibrillation
Other: Patients with Atrial Fibrillation (AF)
Phase 4

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF)

Resource links provided by NLM:


Further study details as provided by Janssen Scientific Affairs, LLC:

Primary Outcome Measures:
  • The primary outcome is stroke or non-CNS (systemic) embolism. Key primary objective is: characterize & describe the AF patient population as a whole, with emphasis on demographics, comorbidities, and risk profiles. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • The number of major adverse cardiac events. [ Time Frame: 3 years ] [ Designated as safety issue: No ]

Enrollment: 10179
Study Start Date: June 2010
Estimated Study Completion Date: November 2014
Estimated Primary Completion Date: November 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
001
Patients with Atrial Fibrillation (AF) Treatment patterns of AF according to patient demographics clinical factors risk stratification and geographic regions.
Other: Patients with Atrial Fibrillation (AF)
Treatment patterns of AF according to patient demographics, clinical factors, risk stratification, and geographic regions.

Detailed Description:

The ORBIT-AF registry is a multicenter prospective outpatient disease registry of patients with incident (initial diagnosis) or prevalent (existing diagnosis) atrial fibrillation (AF) that will analyze treatment patterns and outcomes in patients with AF in the US. Approximately 10,000 prospective cohort of patients will be enrolled. The registry will be a nation-wide collaboration of Health Care Providers (e.g., cardiologists, internists, primary care physicians, electrophysiologists, quality improvement personnel, office/practice managers, research coordinators, and pharmacists). This collaborative effort will be focused on the optimization of outpatient management of patients with AF. Consecutive patients who meet the eligibility criteria will be approached and educated about the registry. Patients who express interest will provide informed consent. Patients enrolled in the registry will be followed for approximately 3 years. Patient follow-up by their AF care provider will continue as scheduled according to local clinical practice. Patient Reported outcome (PRO) questionnaires will be administered to a sub-sample of approximately 1,500 patients. For patients who consent to answer PRO questionnaires, these questionnaires will be administered by the site to the patient at the baseline visit [except the baseline Anticoagulation-Related Treatment Satisfaction (ACTS)] and during their regularly scheduled follow-up visits. The baseline ACTS for incident patients will be completed and returned back to the site at least 4 weeks after starting antithrombotic therapies. The ACTS questionnaire will only be administered to patients who are taking antithrombotic therapies within the 4 weeks before a visit or newly prescribed antithrombotic therapies. Data collection will occur at 6-month intervals for a minimum of 3 years (baseline, 6 months, 12 months, 18 months, 24 months, 30 months, and 36 months). The data collection windows will be wide (3 months in either direction) in order to maximize data collection during the patients regularly scheduled follow-up with their AF care provider. Collection of Patient Reported Outcome (PRO) Questionnaires will not continue beyond the 24-month data collection interval. Atrial Fibrillation Data capture will include demographics, cardiovascular risk factors, diagnosis, type of AF (paroxysmal, persistent, permanent AF), treatment strategy (rate vs. rhythm), ablation history, cardioversions, antithrombotic therapy decisions and monitoring (INRs), concomitant medications and doses, insurance and provider information, AF quality-of-life, anticoagulation treatment satisfaction, caregiver assistance, pet ownership, comorbidities, compliance, and outcomes. Pre-defined outcomes of interest will include stroke or non-CNS (non-systemic) embolism, major adverse cardiac events, all-cause mortality, cause-specific death (sudden, non-sudden, heart failure-related), major bleeding, AF-related quality of life, anticoagulation-related treatment satisfaction, all-cause hospitalization and specific anticoagulation outcomes (e.g. time in therapeutic range and primary discontinuation of oral anticoagulation). The data generated by this registry will be used to identify real world practice, especially as it compares and relates to guidelines set forth by the American College of Cardiology, American Heart Association and European Society of Cardiology for the management of patients with AF. Observational Study - No investigational drug administered. For any patients receiving the sponsor's drug, Xarelto (rivaroxaban), under the direction of a physician, all serious adverse events and all non-serious related events will be reported to the sponsor (Janssen Scientific Affairs, LLC)

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Enrolling physicians will include cardiologists, internists, and electrophysiologists from both academic and private practice who preferably have experience in registry participation.

Criteria

Inclusion Criteria:

  • Adult patients with incident (initial diagnosis) or prevalent (existing diagnosis) AF with electrocardiographic documentation
  • anticipated ability to adhere to local regularly scheduled follow-up visits

Exclusion Criteria:

  • Anticipated life expectancy less than 6 months
  • short lasting AF secondary to a reversible condition (e.g. hyperthyroidism, pulmonary embolism, post-cardiothoracic surgery)
  • Participation in a randomized trial of anticoagulation for AF at the time of enrollment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01165710

  Hide Study Locations
Locations
United States, Alabama
Birmingham, Alabama, United States
Dothan, Alabama, United States
Huntsville, Alabama, United States
Mobile, Alabama, United States
Montgomery, Alabama, United States
Pell City, Alabama, United States
Tuscaloosa, Alabama, United States
United States, Arizona
Cottonwood, Arizona, United States
Tucson, Arizona, United States
United States, Arkansas
Fort Smith, Arkansas, United States
United States, California
Carlsbad, California, United States
Carmichael, California, United States
Corona, California, United States
Laguna Hills, California, United States
Long Beach, California, United States
Los Alamitos, California, United States
Los Angeles, California, United States
Montebello, California, United States
Northridge, California, United States
Orange, California, United States
Oxnard, California, United States
Palo Alto, California, United States
Pismo Beach, California, United States
Pomona, California, United States
San Diego, California, United States
San Ramon, California, United States
Santa Rosa, California, United States
Tarzana, California, United States
Torrance, California, United States
Tustin, California, United States
Ventura, California, United States
United States, Colorado
Aurora, Colorado, United States
Colorado Springs, Colorado, United States
Golden, Colorado, United States
United States, Delaware
Newark, Delaware, United States
Seaford, Delaware, United States
United States, Florida
Boynton Beach, Florida, United States
Coral Springs, Florida, United States
Deerfield Beach, Florida, United States
Fort Myers, Florida, United States
Fort Walton Beach, Florida, United States
Hollywood, Florida, United States
Jupiter, Florida, United States
Lakeland, Florida, United States
Oakland Park, Florida, United States
Orange Park, Florida, United States
Ormond Beach, Florida, United States
Port Charlotte, Florida, United States
St. Petersburg, Florida, United States
Tallahassee, Florida, United States
United States, Georgia
Atlanta, Georgia, United States
Decatur, Georgia, United States
Marietta, Georgia, United States
Riverdale, Georgia, United States
United States, Idaho
Idaho Falls, Idaho, United States
Nampa, Idaho, United States
United States, Illinois
Aurora, Illinois, United States
Evergreen Park, Illinois, United States
Melrose Park, Illinois, United States
Peoria, Illinois, United States
Rock Island, Illinois, United States
Rockford, Illinois, United States
Urbana, Illinois, United States
Winfield, Illinois, United States
United States, Indiana
Bloomington, Indiana, United States
Evansville, Indiana, United States
Hammond, Indiana, United States
Indianapolis, Indiana, United States
La Porte, Indiana, United States
South Bend, Indiana, United States
United States, Iowa
Waterloo, Iowa, United States
United States, Kansas
Overland Park, Kansas, United States
United States, Kentucky
Crestview Hills, Kentucky, United States
Lexington, Kentucky, United States
Owensboro, Kentucky, United States
United States, Louisiana
Alexandria, Louisiana, United States
United States, Maine
Rockport, Maine, United States
United States, Maryland
Beltsville, Maryland, United States
Salisbury, Maryland, United States
United States, Massachusetts
Biddeford, Massachusetts, United States
United States, Michigan
Bay City, Michigan, United States
Bridgman, Michigan, United States
Commerce Township, Michigan, United States
Grand Blanc, Michigan, United States
Lansing, Michigan, United States
Livonia, Michigan, United States
Mount Clemens, Michigan, United States
Sterling Heights, Michigan, United States
Stevensville, Michigan, United States
Traverse City, Michigan, United States
Troy, Michigan, United States
United States, Minnesota
Minneapolis, Minnesota, United States
United States, Montana
Anaconda, Montana, United States
United States, Nebraska
Omaha, Nebraska, United States
United States, Nevada
Las Vegas, Nevada, United States
United States, New Jersey
Bridgewater, New Jersey, United States
Elmer, New Jersey, United States
Haddon Heights, New Jersey, United States
Linden, New Jersey, United States
Nampa, New Jersey, United States
Ridgewood, New Jersey, United States
Sewell, New Jersey, United States
Toms River, New Jersey, United States
United States, New York
Flushing, New York, United States
Huntington, New York, United States
Jamaica, New York, United States
New York, New York, United States
Northport, New York, United States
United States, North Carolina
Calabash, North Carolina, United States
Charlotte, North Carolina, United States
Durham, North Carolina, United States
Greenwood, North Carolina, United States
Jacksonville, North Carolina, United States
Pinehurst, North Carolina, United States
Raleigh, North Carolina, United States
Sanford, North Carolina, United States
Tabor City, North Carolina, United States
Winston Salem, North Carolina, United States
United States, North Dakota
Fargo, North Dakota, United States
Minot, North Dakota, United States
United States, Ohio
Mansfield, Ohio, United States
Miamisburg, Ohio, United States
Piqua, Ohio, United States
Toledo, Ohio, United States
Worthington, Ohio, United States
Youngstown, Ohio, United States
United States, Pennsylvania
Abington, Pennsylvania, United States
Beaver, Pennsylvania, United States
Danville, Pennsylvania, United States
Doylestown, Pennsylvania, United States
Erie, Pennsylvania, United States
Lansdale, Pennsylvania, United States
Philadelphia, Pennsylvania, United States
Scranton, Pennsylvania, United States
Spring House, Pennsylvania, United States
West Reading, Pennsylvania, United States
Wynnewood, Pennsylvania, United States
Yardley, Pennsylvania, United States
United States, Rhode Island
Pawtucket, Rhode Island, United States
United States, South Carolina
Anderson, South Carolina, United States
Easley, South Carolina, United States
Spartanburg, South Carolina, United States
United States, Tennessee
Harriman, Tennessee, United States
Kingsport, Tennessee, United States
Nashville, Tennessee, United States
United States, Texas
Arlington, Texas, United States
Beaumont, Texas, United States
Corpus Christi, Texas, United States
Flower Mound, Texas, United States
Fort Worth, Texas, United States
Houston, Texas, United States
Mcallen, Texas, United States
Odessa, Texas, United States
Plano, Texas, United States
San Antonio, Texas, United States
Tomball, Texas, United States
United States, Utah
Salt Lake City, Utah, United States
United States, Virginia
Fredericksburg, Virginia, United States
Lynchburg, Virginia, United States
Midlothian, Virginia, United States
Roanoke, Virginia, United States
Winchester, Virginia, United States
United States, Washington
Burien, Washington, United States
Port Orchard, Washington, United States
Spokane, Washington, United States
Tacoma, Washington, United States
Vancouver, Washington, United States
United States, Wisconsin
La Crosse, Wisconsin, United States
Madison, Wisconsin, United States
Puerto Rico
Hato Rey, Puerto Rico
Rio Grande, Puerto Rico
San Juan, Puerto Rico
Sponsors and Collaborators
Janssen Scientific Affairs, LLC
Duke Clinical Research Institute
Investigators
Study Director: Janssen Scientific Affairs, LLC Clinical Trial Janssen Scientific Affairs, LLC
  More Information

No publications provided by Janssen Scientific Affairs, LLC

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Responsible Party: Janssen Scientific Affairs, LLC
ClinicalTrials.gov Identifier: NCT01165710     History of Changes
Other Study ID Numbers: CR016327, RIVAROXAFL4001
Study First Received: July 16, 2010
Last Updated: September 11, 2014
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration

Keywords provided by Janssen Scientific Affairs, LLC:
Irregular heart beat

Additional relevant MeSH terms:
Atrial Fibrillation
Arrhythmias, Cardiac
Heart Diseases
Cardiovascular Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on October 20, 2014